Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4543MR)

This product GTTS-WQ4543MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4543MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4501MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ1554MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ7207MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ12322MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MT203
GTTS-WQ12859MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ2971MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ANB020
GTTS-WQ8092MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ9342MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA INCAGN-01876
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW